Skip to main content
Erschienen in: Wiener klinische Wochenschrift 3-4/2022

22.03.2021 | original article

Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?

verfasst von: Şengül Aydın Yoldemir, MD, Guzin Zeren Ozturk, Murat Akarsu, Mustafa Ozcan

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2022

Einloggen, um Zugang zu erhalten

Summary

Background

One of the electrolyte disorders considered to be linked to proton pump inhibitors (PPI) use is hypomagnesemia. The aim of this study was to assess the incidence of hypomagnesemia linked to long-term PPI use and the correlation with active agents.

Methods

The study included 305 patients aged over 18 years with PPI use of 1 year or longer and attending the internal diseases clinic for any reason from April 2019 to December 2019. A survey study was performed about the demographic characteristics and PPI use of patients. Laboratory parameters, such as the hemogram, magnesium, phosphorus, calcium and vitamin B12 concentrations were recorded. Magnesium concentrations were measured by a colorimetric method.

Results

Of the patients 140 (45.9%) were female and 165 (54.1%) were male. The most commonly used PPI active agent was pantoprazole. The duration of PPI use varied from 1–25 years with a mean of 4.31 ± 4.52 years. Of the patients 51.5% reported no medication side effects. The most commonly observed side effect was constipation (n = 98, 32.1%). The mean magnesium concentration was 1.95 ± 0.02 mg/dL. Hypomagnesemia was identified in 65 (21.3%) patients and the incidence increased as age and duration of use increased. Patients using omeprazole had significantly lower magnesium levels compared to patients using pantoprazole, rabeprazole, esomeprazole and lansoprazole.

Conclusion

In light of the data obtained it was concluded that hypomagnesemia linked to PPI use is associated with the type of PPI. While patients using rabeprazole had the lowest rates, those using omeprazole had significantly higher rates of hypomagnesemia. Additionally, there was a proportional correlation between age and duration of use with the risk of development of hypomagnesemia.
Literatur
2.
Zurück zum Zitat Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. Arch Intern Med. 2010;170:784–90.CrossRef Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. Arch Intern Med. 2010;170:784–90.CrossRef
3.
Zurück zum Zitat Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–8.CrossRef Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–8.CrossRef
4.
Zurück zum Zitat Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–47.CrossRef Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–47.CrossRef
5.
Zurück zum Zitat Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50.CrossRef Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50.CrossRef
6.
Zurück zum Zitat Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21:3–8.CrossRef Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21:3–8.CrossRef
7.
Zurück zum Zitat Flink EB. Magnesium deficiency. Etiology and clinical spectrum. Acta Med Scand Suppl. 1981;647:125–37.PubMed Flink EB. Magnesium deficiency. Etiology and clinical spectrum. Acta Med Scand Suppl. 1981;647:125–37.PubMed
8.
Zurück zum Zitat Vallee BL, Wacker WE, Ulmer DD. The magnesium-deficiency tetany syndrome in man. N Engl J Med. 1960;262:155–61.CrossRef Vallee BL, Wacker WE, Ulmer DD. The magnesium-deficiency tetany syndrome in man. N Engl J Med. 1960;262:155–61.CrossRef
9.
Zurück zum Zitat Moore MJ, Flink EB. Magnesium deficiency as a cause of serious arrhythmias. Arch Intern Med. 1978;138:825–6.CrossRef Moore MJ, Flink EB. Magnesium deficiency as a cause of serious arrhythmias. Arch Intern Med. 1978;138:825–6.CrossRef
10.
Zurück zum Zitat Barbagallo M, Dominguez LJ, Galioto A, et al. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res. 2010;23(3):131–7. Barbagallo M, Dominguez LJ, Galioto A, et al. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res. 2010;23(3):131–7.
11.
Zurück zum Zitat Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys. 2007;458(1):40–7.CrossRef Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys. 2007;458(1):40–7.CrossRef
12.
Zurück zum Zitat Reffelmann T, Ittermann T, Dörr M, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011;219(1):280–4.CrossRef Reffelmann T, Ittermann T, Dörr M, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011;219(1):280–4.CrossRef
13.
Zurück zum Zitat FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPİs). 2011. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPİs). 2011.
14.
Zurück zum Zitat Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47:773–80.CrossRef Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47:773–80.CrossRef
15.
Zurück zum Zitat Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83:692–9.CrossRef Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83:692–9.CrossRef
17.
Zurück zum Zitat Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69(2):338–41.CrossRef Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69(2):338–41.CrossRef
18.
Zurück zum Zitat Schmitz C, Perraud AL, Johnson CO, et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell. 2003;114:191–200.CrossRef Schmitz C, Perraud AL, Johnson CO, et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell. 2003;114:191–200.CrossRef
19.
Zurück zum Zitat Bai JP, Hausman E, Lionberger R, et al. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. Mol Pharmacol. 2012;9:3495–505.CrossRef Bai JP, Hausman E, Lionberger R, et al. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. Mol Pharmacol. 2012;9:3495–505.CrossRef
20.
Zurück zum Zitat Lewis JL. Hypomagnesemia. 2020. Last full review/revision Apr 2020. Lewis JL. Hypomagnesemia. 2020. Last full review/revision Apr 2020.
21.
Zurück zum Zitat Khara HS, Pitchumoni CS. Proton pump inhibitors: a better prescription is needed. J Clin Gastroenterol. 2009;6:597–8.CrossRef Khara HS, Pitchumoni CS. Proton pump inhibitors: a better prescription is needed. J Clin Gastroenterol. 2009;6:597–8.CrossRef
22.
Zurück zum Zitat Bilginer E. Türkiye’de 2006–2011 yıllarında proton pompası inhibitörleri tüketiminin bütçeye etkisi. Ankara Ecz Fak Derg. 2018;42(2):23–31. Bilginer E. Türkiye’de 2006–2011 yıllarında proton pompası inhibitörleri tüketiminin bütçeye etkisi. Ankara Ecz Fak Derg. 2018;42(2):23–31.
23.
Zurück zum Zitat Özden A. Proton pompa inhibitörleri ve kullanım güvenirliği. Güncel Gastroenteroloji Dergisi. 2013;17:179–204. Özden A. Proton pompa inhibitörleri ve kullanım güvenirliği. Güncel Gastroenteroloji Dergisi. 2013;17:179–204.
24.
Zurück zum Zitat Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553–6.CrossRef Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553–6.CrossRef
25.
Zurück zum Zitat Rondón LJ, Groenestege WM, Rayssiguier Y, et al. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol. 2008;294(6):R2001–7.CrossRef Rondón LJ, Groenestege WM, Rayssiguier Y, et al. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol. 2008;294(6):R2001–7.CrossRef
26.
Zurück zum Zitat Dimke H, Monnens L, Hoenderop JG, et al. Evaluation of hypomagnesemia: lessons from disorders of tubular transport. Am J Kidney Dis. 2013;62(2):377–83.CrossRef Dimke H, Monnens L, Hoenderop JG, et al. Evaluation of hypomagnesemia: lessons from disorders of tubular transport. Am J Kidney Dis. 2013;62(2):377–83.CrossRef
27.
Zurück zum Zitat Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham heart study. Circulation. 2013;127(1):33–8.CrossRef Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham heart study. Circulation. 2013;127(1):33–8.CrossRef
28.
Zurück zum Zitat Markovits N, Loebstein R, Halkin H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014;54:889–95.CrossRef Markovits N, Loebstein R, Halkin H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014;54:889–95.CrossRef
29.
Zurück zum Zitat Bahtiri E, Islami H, Hoxha R, et al. Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study. Turk J Gastroenterol. 2017;28:104–9.CrossRef Bahtiri E, Islami H, Hoxha R, et al. Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study. Turk J Gastroenterol. 2017;28:104–9.CrossRef
31.
Zurück zum Zitat Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126(3):256–63.CrossRef Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126(3):256–63.CrossRef
33.
Zurück zum Zitat Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco‑2 monolayers. World J Gastroenterol. 2011;17:1574–83.CrossRef Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco‑2 monolayers. World J Gastroenterol. 2011;17:1574–83.CrossRef
34.
Zurück zum Zitat Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.CrossRef Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.CrossRef
Metadaten
Titel
Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?
verfasst von
Şengül Aydın Yoldemir, MD
Guzin Zeren Ozturk
Murat Akarsu
Mustafa Ozcan
Publikationsdatum
22.03.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2022
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01834-x

Weitere Artikel der Ausgabe 3-4/2022

Wiener klinische Wochenschrift 3-4/2022 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Wiener klinische Wochenschrift

MUW researcher of the month

MUW researcher of the month